


CLAIMS

What is claimed is:

1. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II''):



wherein

X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X8 is Gln, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, or Trp;

X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);

X10 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy;

X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;

X13 is Aib, Glu, Cit, Gln, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or

X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;

X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gln, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);

X15 Leu, (D)Leu, beta-Ala, Cit, or (D)Lys;


R² is OH or NH₂;

or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;

and

wherein the peptide inhibitor or pharmaceutically acceptable salt of solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.

2. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (I'):




wherein

X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);

X5 is Cit, Glu, Gly, Leu, Ile, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Gln, Asp, or Cys; and

X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, alpha-MeThr, alpha-MeSer, or Val.

3. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor is according to Formula (Z'):



or a pharmaceutically acceptable salt or solvate thereof, wherein

X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);

X5 is Cit, Glu, Gly, Leu, Ile, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Gln, Asp, or Cys; and

X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, alpha-MeThr, alpha-MeSer, or Val;

X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X8 is Gln, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, or Trp;

X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);

X10 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminoethoxy;

X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;

X13 is Aib, Glu, Cit, Gln, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or

X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;

X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gln, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);

X15 Leu, (D)Leu, beta-Ala, Cit, or (D)Lys;

R¹ is hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-C1-C6alkyl, or a C1-C20 alkanoyl;

R² is OH or NH₂;

wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;

and

wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.

4. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises or is any one of the following, or a pharmaceutically acceptable salt or solvate thereof:

SEQ ID NO:	Sequence
201	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH ₂

SEQ ID NO:	Sequence
202	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
203	Ac-[(D)Arg]-Abu-Q-T-[W(7-Me)]-Q-C-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH ₂
204	Ac-Abu-Q-T-[W(7-Me)]-Q-C-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH ₂
205	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-G-[bA]-NH ₂
206	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[Cit]-[bA]-NH ₂
207	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-A-[bA]-NH ₂
208	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-L-[bA]-NH ₂
209	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Ala]-[bA]-NH ₂
214	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-H-[bA]-NH ₂
217	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-T-[bA]-NH ₂
221	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-S-[bA]-NH ₂
222	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Ser]-[bA]-NH ₂
226	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[bA]-[bA]-NH ₂
227	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH ₂
228	Ac-[Pen]-NT-[W(6-Cl)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂

SEQ ID NO:	Sequence
229	Ac-[Pen]-NT-[W(4-OMe)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
230	Ac-[Pen]-NT-[W(6-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
231	Ac-[Pen]-NT-[W(4-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
232	Ac-[Pen]-NT-[W(1-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
233	Ac-[Pen]-NT-[W(2,5,7-tritBu)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
234	Ac-[Pen]-NT-[W(7-Me)]-[a-MeLys]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH ₂
235	Ac-[Pen]-NT-[W(7-Me)]-[a-MeLeu]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
236	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Aib]-N-[bA]-NH ₂
237	Ac-[Pen]-Q-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
238	Ac-[Pen]-[Cit]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
239	Ac-[Pen]-[Lys(Ac)]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
240	Ac-[Pen]-[Aib]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
241	Ac-[Pen]-NT-[W(7-Me)]-[Aib]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
242	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
244	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-L-NH ₂


SEQ ID NO:	Sequence
245	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂
249	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Cit]-NH ₂
252	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂
267	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂
268	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[bA]-[bA]-NH ₂
269	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-L-[bA]-NH ₂
270	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[bA]-[bA]-NH ₂
271	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-S-[bA]-NH ₂
272	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-H-[bA]-NH ₂
273	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-[bA]-[bA]-NH ₂
279	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Cit]-[bA]-[bA]-NH ₂
280	Ac-[Pen]-N-T-[W(1-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[bA]-[bA]-NH ₂
281	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Cit]-[bA]-[bA]-NH ₂
282	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-N-[bA]-NH ₂
283	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[W(1-Me)]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH ₂

SEQ ID NO:	Sequence
284	Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂
285	Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂
286	Ac-[Pen]-N-T-[W(7-i-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂
288	Ac-[Pen]-N-T-[W(7-OMe)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂
296	Ac-[Pen]-N-T-[W(5-CN)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂
297	Ac-[Pen]-N-T-[W(7-OMe)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂
299	Ac-[Pen]-N-T-[W(7-OMe)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂
300	Ac-[Pen]-N-T-[W(7-OMe)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂
314	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ala)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
315	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(IVA)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
316	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(cyclohexanoic)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
317	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(octanoic)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
318	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(C(O)CH ₂ Ph)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
319	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(trifluoropropionic)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
320	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;

SEQ ID NO:	Sequence
321	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(bAla)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
322	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Aib)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
324	Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂ ;
325	Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
328	Ac-[Pen]-A-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
329	Ac-[Pen]-G-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
330	Ac-[Pen]-[Lys(Ac)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
331	Ac-[Pen]-[Cit]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
332	Ac-[Pen]-L-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
333	Ac-[Pen]-P-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
334	Ac-[Pen]-S-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
335	Ac-[Pen]-[Dab(Ac)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
336	Ac-[Pen]-R-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
337	Ac-[Pen]-[hLeu]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;
338	Ac-[Pen]-[(D)Asn]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂ ;

SEQ ID NO:	Sequence
349	Ac-[Pen]-N-T-[W(6-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂ ;
351	Ac-[Pen]-N-T-[W(2-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂ ;
352	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-S-[(D)Lys]-NH ₂ ;
353	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[W(2-Me)]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂ ;
355	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ala)]-N-[(D)Leu]-NH ₂ ;
362	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(PEG3-OMe)]-N-[(D)Leu]-NH ₂ ; or
363	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(PEG11-OMe)]-N-[(D)Leu]-NH ₂

5. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II):



wherein

X4 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen, or Pen(sulfoxide);

X5 is Cit, Glu, Gly, Leu, Ile, beta-Ala, Ala, Lys, Asn, Pro, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, Lys(Ac), alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Gln, Asp, or Cys; and

X6 is Thr, Aib, Asp, Dab, Gly, Pro, Ser, alpha-MeGln, alpha-MeLys, alpha-MeLeu, alpha-MeAsn, alpha-MeThr, alpha-MeSer, or Val.

6. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 or X9 is Cys, (D)Cys, alpha-MeCys, (D)Pen, or Pen; and the bond between X4 and X9 is a disulfide bond.
7. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 is (D)Pen, or Pen; or X4 is Pen(sulfoxide).
8. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 is Pen.
9. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-8, wherein X9 is Cys, (D)Cys, or alpha-MeCys.
10. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-8, wherein X9 is Pen or (D)Pen.
11. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-8, wherein X9 is Pen.
12. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 is Pen and X9 is Pen, and the bond is a disulfide bond.
13. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein X4 or X9 is Abu; and the bond between X4 and X9 is a thioether bond.
14. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IIa) (IIb), or (IIc):

Pen-X5-X6-X7-X8-Pen-X10-X11 (IIa),
Abu-X5-X6-X7-X8-Cys-X10-X11 (IIb), or
Abu-X5-X6-X7-X8-Pen-X10-X11 (IIc),

wherein X5-X8 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or the peptide inhibitor is cyclized via a Abu-Cys or Abu-Pen thioether bond.

15. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-14, wherein X5 is Asn, Gln, or Glu.

16. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-14, wherein X5 is Asn, or Gln.

17. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-14, wherein X5 is Asn.

18. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IIIa), (IIIb), (IIIc), or (IIId):

Pen- Asn-X6-X7-X8-Pen-X10-X11 (IIIa),

Pen-Gln-X6-X7-X8-Pen-X10-X11 (IIIb),

Abu- Asn-X6-X7-X8-Cys-X10-X11 (IIIc), or

Abu-Gln-X6-X7-X8-Pen-X10-X11 (IIId),

wherein X6-X8 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

19. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-18, wherein X6 is Thr.

20. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IVa), (IVb), (IVc), or (IVd):

Pen- Asn-Thr-X7-X8-Pen-X10-X11 (IVa),

Pen-Gln-Thr-X7-X8-Pen-X10-X11 (IVb),

Abu- Asn-Thr-X7-X8-Cys-X10-X11 (IVc), or

Abu-Gln-Thr-X7-X8-Pen-X10-X11 (IVd),

wherein X7-X8 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

21. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-20, wherein X8 is Gln, alpha-Me-Lys, alpha-MeLys(Ac), or Glu.

22. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-20, wherein X8 is Gln.

23. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Va), (Vb), (Vc), or (Vd):

Pen- Asn-Thr-X7-Gln-Pen-X10-X11 (Va),

Pen-Gln-Thr-X7-Gln-Pen-X10-X11 (Vb),

Abu-Asn-Thr-X7-Gln-Cys-X10-X11 (Vc), or

Abu-Gln-Thr-X7-Gln-Pen-X10-X11 (Vd)

wherein X7 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

24. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (Ve), (Vf), (Vg), or (Vh):

Pen-Asn-Thr-X7-Lys(Ac)-Pen-X10-X11 (Ve),

Pen-Gln-Thr-X7-Lys(Ac)-Pen-X10-X11 (Vf),

Abu-Asn-Thr-X7-Lys(Ac)-Cys-X10-X11 (Vg), or

Abu-Gln-Thr-X7-Lys(Ac)-Pen-X10-X11 (Vh)

wherein X7 and X10-X11 are as described in claim 1; and the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a Abu-Cys or Abu-Pen thioether bond.

25. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-24, wherein X10 is Phe, Phe[4-(2-aminoethoxy)], Phe[4-(2-acetylaminoethoxy)], or Phe(4-CONH₂).

26. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-24, wherein X10 is Phe[4-(2-aminoethoxy)], or Phe[4-(2-acetylaminoethoxy)].

27. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIa), (VIb), (VIc), or (VId):

Pen- Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11 (VIa),

Pen-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11 (VIb),

Abu-Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11 (VIc), or

Abu-Gln-Thr-X7-Gln-Pen-[F(4-2ae)]-X11 (VId)

wherein X7 and X11 are as described in claim 1; [F(4-2ae)] is Phe[4-(2-aminoethoxy)].

28. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIe), (VIf), (VIg), or (VIh):

Pen-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11 (VIe),

Pen-Gln-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11 (VIf),

Abu-Asn-Thr-X7-Lys(Ac)-Cys-[F(4-2ae)]-X11 (VIg), or

Abu-Gln-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11 (VIh)

wherein X7 and X11 are as described in claim 1; [F(4-2ae)] is Phe[4-(2-aminoethoxy)].

29. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIIa), (VIIb), or (VIIc):

Pen- Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIa),

Abu- Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIb), or

Abu- Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIc)

wherein X7 and X11-X15 are as described in claim 1.

30. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIId), (VIIe), or (VIIf) or comprises a sequence of Formula (VIId), (VIIe), or (VIIf):

Pen-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIId),

Abu-Asn-Thr-X7-Lys(Ac)-Cys-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIe), or

Abu-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11-X12-X13-X14-X15 (VIIf)

wherein X7 and X11-X15 are as described in claim 1.

31. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-30, wherein X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, Ala, cyclohexylAla, Lys, or Aib.

32. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-30, wherein X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, or alpha-MeLeu.

33. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-30, wherein X12 is alpha-MeLeu.

34. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-31, wherein X13 is Glu, Gln, Lys(Ac), or Lys.

35. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-31, wherein X13 is Gln, Lys(Ac), or Lys.

36. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-31, wherein X13 is Lys(Ac), or Lys.

37. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-31, wherein X13 is Lys(Ac).

38. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIIIa), (VIIIb) or (VIIIc):

Pen-Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-aMeLeu-K(Ac)-X14-X15 (VIIIa),

Abu-Asn-Thr-X7-Gln-Cys-[F(4-2ae)]-X11-aMeLeu-K(Ac)-X14-X15 (VIIIb), or

Abu-Asn-Thr-X7-Gln-Pen-[F(4-2ae)]-X11-aMeLeu-K(Ac)-X14-X15 (VIIIc)

wherein X7, X11, X14, and X15 are as described in claim 1.

39. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (VIIId), (VIIIe) or (VIIIf) or comprises a sequence of Formula (VIIId), (VIIIe) or (VIIIf):

Pen-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11-[alpha-MeLys]-K(Ac)-X14-X15
(VIIId),

Abu-Asn-Thr-X7-Lys(Ac)-Cys-[F(4-2ae)]-X11-[alpha-MeLys]-K(Ac)-X14-X15
(VIIIe), or

Abu-Asn-Thr-X7-Lys(Ac)-Pen-[F(4-2ae)]-X11-[alpha-MeLys]-K(Ac)-X14-X15 (VIIIf)
wherein X7, X11, X14, and X15 are as described in claim 1.

40. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-39, wherein X7 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; and X11 is as described in claim 1.

41. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; and X7 is as described in claim 1.


42. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal.

43. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is 2-Nal, or 1-Nal.

44. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is 2-Nal.

45. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-40, wherein X11 is 1-Nal.

46. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 1, wherein the peptide inhibitor comprises an amino acid sequence of Formula (IVa):



wherein X8, X10, and X11 are as in claim 1, and X7 is Trp substituted with alkyl, and the substitution is at 1-, 2, or 7-position.

47. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 46, wherein X7 is Trp substituted with 1-Me, 2-Me, or 7-Me.

48. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-47, wherein X8 is Gln, alpha-Me-Lys, alpha-MeLys(Ac), or Glu.

49. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-47, wherein X8 is Gln.

50. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-47, wherein X8 is Q, Cit, a-MeLys, a-MeLeu, Aib, Lys(Ac), Lys(Gly), or Lys(Aib).

51. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-47, wherein X8 is Lys(Ac).

52. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-51, wherein X10 is Phe, Phe[4-(2-aminoethoxy)], Phe[4-(2-acetylaminoethoxy)], or Phe(4-CONH₂).

53. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-51, wherein X10 is Phe[4-(2-aminoethoxy)], or Phe[4-(2-acetylaminoethoxy)].

54. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-53, wherein X11 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy.

55. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-53, wherein X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), or 1-Nal.

56. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-53, wherein X11 is 2-Nal, or 1-Nal.

57. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 46-53, wherein X11 is 2-Nal.

58. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-57, wherein the peptide inhibitor comprises the structure of Formula (Z):



or a pharmaceutically acceptable salt or solvate thereof, wherein

R¹ is hydrogen, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-C1-C6alkyl, or a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing;


X is the amino acid sequence of Formula (I), any of Formula (II)-(XII), or an amino acid sequence set forth in Table E3; and

R² is OH or NH₂.


59. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 58, wherein X is the amino acid sequence of Formula (II').

60. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 58, wherein the peptide comprises X-R², and X is the amino acid sequence of Formula (II'), and R² is OH or NH₂.

61. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 58, wherein the peptide comprises an amino acid sequence of Formula (II''):



62. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-61, wherein the peptide inhibitor comprises the structure of Formula (Z):



or a pharmaceutically acceptable salt or solvate thereof, wherein

R¹ is a bond, hydrogen, Ac, a C1-C6 alkyl, a C6-C12 aryl, a C6-C12aryl-C1-C6alkyl, or a C1-C20 alkanoyl, and including PEGylated versions alone or as spacers of any of the foregoing;

X is the amino acid sequence of Formula (II'); and

R² is OH or NH₂;

or wherein the peptide inhibitor of Formula (Z) is a peptide having an amino acid sequence set forth in Table E3 or a pharmaceutically acceptable salt or solvate thereof.

63. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 58-62, wherein R¹ is H or C1-C20 alkanoyl.

64. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 58-62, wherein R¹ is H or Ac.

65. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof any one of claims 58-62, wherein R¹ is Ac.

66. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 201);

Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 227);

Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 242);

Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 245);

Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Cit]-NH₂ (SEQ ID NO: 249);

Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH₂ (SEQ ID NO: 252);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 267);

Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 284);

Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 285);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂; (SEQ ID NO: 320); or

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Aib)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂; (SEQ ID NO: 322);

and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via an Abu-C thioether bond;

or a pharmaceutically acceptable salt or solvate thereof.

67. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 202);

Ac-[(D)Arg]-Abu-Q-T-[W(7-Me)]-Q-C-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH₂ (SEQ ID NO: 203);

Ac-Abu-Q-T-[W(7-Me)]-Q-C-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH₂ (SEQ ID NO: 204);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-G-[bA]-NH₂ (SEQ ID NO: 205);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-A-[bA]-NH₂ (SEQ ID NO: 207);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-L-[bA]-NH₂ (SEQ ID NO: 208);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Ala]-[bA]-NH₂ (SEQ ID NO: 209);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-H-[bA]-NH₂ (SEQ ID NO: 214);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-T-[bA]-NH₂ (SEQ ID NO: 217);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-S-[bA]-NH₂ (SEQ ID NO: 221);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Ser]-[bA]-NH₂ (SEQ ID NO: 222);

Ac-[Pen]-NT-[W(4-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 231);

Ac-[Pen]-NT-[W(1-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 232);

Ac-[Pen]-NT-[W(7-Me)]-[a-MeLys]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 234);

Ac-[Pen]-NT-[W(7-Me)]-[a-MeLeu]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 235);

Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Aib]-N-[bA]-NH₂ (SEQ ID NO: 236);

Ac-[Pen]-Q-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 237);

Ac-[Pen]-[Cit]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 238);

Ac-[Pen]-[Lys(Ac)]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 239);

Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-L-NH₂ (SEQ ID NO: 244);

Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-[bA]-[bA]-NH₂ (SEQ ID NO: 268);

Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
L-[bA]-NH₂ (SEQ ID NO: 269);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-[bA]-[bA]-NH₂ (SEQ ID NO: 270);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-S-[bA]-NH₂ (SEQ ID NO: 271);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-H-[bA]-NH₂ (SEQ ID NO: 272);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-
[bA]-[bA]-NH₂ (SEQ ID NO: 273);

Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Cit]-[bA]-
[bA]-NH₂ (SEQ ID NO: 279);

Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-E-N-[bA]-
NH₂ (SEQ ID NO: 282);

Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[W(1-Me)]-[a-MeLys]-
[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 283);

Ac-[Pen]-N-T-[W(7-i-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 286);

Ac-[Pen]-N-T-[W(7-OMe)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 288);

Ac-[Pen]-N-T-[W(7-OMe)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
N-[(D)Lys]-NH₂ (SEQ ID NO: 297);

Ac-[Pen]-N-T-[W(7-OMe)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Lys]-NH₂ (SEQ ID NO: 299);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ala)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂; (SEQ ID NO: 314);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(IV A)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂; (SEQ ID NO: 315);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(cyclohexanoic)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂; (SEQ ID NO: 316);

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(bAla)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂; (SEQ ID NO: 321); or


Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂; (SEQ ID NO: 325);

and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via a Abu-C thioether bond;


or a pharmaceutically acceptable salt or solvate thereof.

68. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:


Ac-[Pen]-[Cit]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (Seq. ID. No. 238)




Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (Seq. ID. No. 242)




Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (Seq. ID. No. 245)




Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[Cit]-NH₂ (Seq. ID. No. 249)




Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Lys]-NH₂ (Seq. ID. No. 252)




Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-
[bA]-NH₂ (Seq. ID. No. 267)




Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (Seq. ID. No. 284)




Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (Seq. ID. No. 285)




Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 320)



Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Aib)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 322)




Ac-[Pen]-[Dab(Ac)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 335)




and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond;
or a pharmaceutically acceptable salt or solvate thereof.

69. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-[Cit]-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[bA]-NH₂ (Seq. ID. No. 238)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically
acceptable salt or solvate thereof.

70. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[bA]-NH₂ (Seq. ID. No. 242)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

71. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (Seq. ID. No. 245)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

72. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[Cit]-NH₂ (Seq. ID. No. 249)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

73. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH₂ (Seq. ID. No. 252)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

74. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is: Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bA]-NH₂ (Seq. ID. No. 267)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

75. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-N-T-[W(7-Et)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (Seq. ID. No. 284)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

76. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-N-T-[W(7-n-Pr)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (Seq. ID. No. 285)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

77. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Gly)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 320)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

78. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Aib)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 322)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.


79. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-[Dab(Ac)]-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 335)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

80. The peptide inhibitor of claim 1, wherein the peptide inhibitor comprises or is:
Ac-[(D)Arg]-Abu-Q-T-[W(5-F)]-Q-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-E-N-[bA]-NH₂
(SEQ ID NO: 364).

81. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (I):



wherein

X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X8 is Gln, α -MeLys, α -MeLeu, α -MeLys(Ac), β -homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, α -MeGln, α -MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, or Trp;

X9 is Abu, Cys, (D)Cys, α -MeCys, (D)Pen, Pen or Pen(sulfoxide);

X10 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, or 2-acetylaminethoxy; and

X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

and

provided that

i) at least one of X7 and X11 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

ii) X7 is other than 5-F substituted Trp;

iii) when X7 is unsubstituted Trp, or Trp substituted with 1-Me, 5-OH or 6-Cl; then X9 is other than Cys; and

iv) the compound is other than

Ac-[Pen]-NT-[W(5-Cl)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 1);

Ac-[Pen]-NT-[W(6-Cl)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 2);

Ac-[Pen]-NT-[W(6-F)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 3);

Ac-[Pen]-NT-[W(4-OMe)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 4);

Ac-[Pen]-NT-[W(6-Me)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-
[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 5);

Ac-[Pen]-NT-[W(7-Me)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-
[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 6);

Ac-[Pen]-NT-[W(5-F)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-[Lys(Ac)]-
NN-NH₂ (SEQ ID NO: 7);

Ac-[Pen]-NT-[W(7-F)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-[Lys(Ac)]-
NN-NH₂ (SEQ ID NO: 8);

Ac-[Pen]-NT-[W(5-OMe)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-
[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 9);

Ac-[Pen]-NT-[W(5-OH)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-
[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 10);

Ac-[Pen]-NT-[W(5-Br)]-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-[2-Nal]-[α -MeLeu]-[Lys(Ac)]-
NN-NH₂ (SEQ ID NO: 11);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-W(5-Cl)-[α -MeLeu]-[Lys(Ac)]-NN-
NH₂ (SEQ ID NO: 12);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-W(6-Cl)-[α -MeLeu]-[Lys(Ac)]-NN-
NH₂ (SEQ ID NO: 13);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-W(6-F)-[α -MeLeu]-[Lys(Ac)]-NN-NH₂
(SEQ ID NO: 14);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-W(4-OMe)-[α -MeLeu]-[Lys(Ac)]-NN-
NH₂ (SEQ ID NO: 15);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-W(6-Me)-[α -MeLeu]-[Lys(Ac)]-NN-
NH₂ (SEQ ID NO: 16);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-W(7-Me)-[α -MeLeu]-[Lys(Ac)]-NN-
NH₂ (SEQ ID NO: 17);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-W(5-F)-[α -MeLeu]-[Lys(Ac)]-NN-NH₂
(SEQ ID NO: 18);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-W(7-F)-[α -MeLeu]-[Lys(Ac)]-NN-NH₂
(SEQ ID NO: 19);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]]-W(5-OMe)-[α -MeLeu]-[Lys(Ac)]-NN-
NH₂ (SEQ ID NO: 20);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(5-OH)-[α-MeLeu]-[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 21);

Ac-[Pen]-NTW-Gln-[Pen]-[Phe[4-(2-aminoethoxy)]-W(5-Br)-[α-MeLeu]-[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 22);

Ac-[(D)Arg]-[Abu]-QT-[W(7-Me)]-QC-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-ENN-NH₂ (SEQ ID NO: 27);

Ac-[Abu]-QT-[W(7-Me)]-QC-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-ENN-NH₂ (SEQ ID NO: 28);

Ac-[(D)Arg]-[Abu]-QT-[W(7-Me)]-QC-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 29); or


Ac-[Abu]-QT-[W(7-Me)]-QC-[Phe[4-(2-aminoethoxy)]-[2-Nal]-[THP]-[Lys(Ac)]-NN-NH₂ (SEQ ID NO: 30);

wherein Pen-Pen form a disulfide bond, or Abu-Cys form a thioether bond;

and

wherein the peptide inhibitor inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.

82. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 81, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II'):



and wherein

X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, or Aib;


X13 is Aib, Glu, Cit, Gln, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys; or

X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;

X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gln, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or Lys(Ac);

X15 is Asn, Leu, Aib, (D)Leu, beta-Ala, Cit, Gln, Asp, alpha-MeGln, alpha-MeAsn, Lys(Ac), (D)Lys, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), or absent.

83. A peptide inhibitor of an interleukin-23 receptor, or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor comprises an amino acid sequence of Formula (II'):



wherein

X7 is unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X8 is Gln, alpha-MeLys, alpha-MeLeu, alpha-MeLys(Ac), beta-homoGln, Cit, Glu, Phe, Asn, Thr, Val, Aib, alpha-MeGln, alpha-MeAsn, Lys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), 1-Nal, 2-Nal, or Trp;

X9 is Abu, Cys, (D)Cys, alpha-MeCys, (D)Pen, Pen or Pen(sulfoxide);

X10 is unsubstituted Phe, or Phe substituted with halo, alkyl, haloalkyl, hydroxy, alkoxy, carboxy, carboxamido, 2-aminoethoxy, 2-acetylaminoethoxy, 2-Nal, His, His_3Bom, or His_Bzl;

X11 is 2-Nal, Phe(2-Me), Phe(3-Me), Phe(4-Me), Phe(3,4-dimethoxy), 1-Nal, unsubstituted Trp, or Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy;

X12 is 4-amino-4-carboxy-tetrahydropyran (THP), alpha-MeLys, alpha-MeLeu, alpha-MeArg, alpha-MePhe, alpha-MeLeu, alpha-MeLys, alpha-MeAsn, alpha-MeTyr, Ala, or cyclohexylAla, Lys, Aib, Achc, Spiral-Pip, DiethylGly, Acbc, or a-MeOrn;

X13 is Aib, Glu, Cit, Gln, Lys(Ac), alpha-MeArg, alpha-MeGlu, alpha-MeLeu, alpha-MeLys, alpha-Me-Asn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Lys, or Gly; or X13 is Lys, pegylated Lys, b-homoGlu, or Lys(Y2-Ac), wherein Y2 is an amino acid;

X14 is Asn, 2-Nap, Aib, Arg, Cit, Asp, Phe, Gly, Lys, Leu, Ala, (D)Ala, beta-Ala, His, Thr, n-Leu, Gln, Ser, (D)Ser, Tic, Trp, alpha-MeGln, alpha-MeAsn, alpha-MeLys(Ac), Dab(Ac), Dap(Ac), homo-Lys(Ac), Lys(Ac), (D)Leu, Pro, (D)Pro, (D)Phe, (D)His, Ile, (D)Thr, Gly, N-MeAla, Sarc, or aMeLeu;

X15 Leu, (D)Leu, beta-Ala, Cit, (D)Lys Arg, NMeArg, bhPhe, His, Val, (D)Val, (D)Lys, Pro, (D)Pro, Ile, (D)Arg, (D)Phe, (D)Tyr, Ser, (D)Ser, Thr, (D)Thr, N-MeAla, Y, a-MePhe, Sarc, Gly, Ala, (D)Tyr, (D)2-Nal, (D)Asn, or absent;

and

provided that at least one of X7 and X11 is Trp substituted with cyano, halo, alkyl, haloalkyl, hydroxy, or alkoxy; or the peptide inhibitor is

SEQ ID NO: 264	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-NH ₂
-------------------	--

or

SEQ ID NO: 340	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[bA]-NH ₂
-------------------	--

84. The peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of claim 83, wherein the peptide inhibitor comprises or is any one of the following or a pharmaceutically acceptable salt or solvate thereof:

SEQ ID NO:	Sequence*
210	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Leu]-[bA]-NH ₂
211	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-P-[bA]-NH ₂
212	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Pro]-[bA]-NH ₂
213	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Phe]-[bA]-NH ₂
215	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)His]-[bA]-NH ₂
216	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-I-[bA]-NH ₂
218	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)Thr]-[bA]-NH ₂
219	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-G-P-[bA]-NH ₂

SEQ ID NO:	Sequence*
220	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-G-[(D)Pro]-[bA]-NH ₂
223	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[N-MeAla]-[bA]-NH ₂
224	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[Sarc]-[bA]-NH ₂
225	Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[a-MeLeu]-[bA]-NH ₂
243	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-R-NH ₂
246	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[NMeArg]-NH ₂
247	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bhPhe]-NH ₂
248	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-NH ₂
250	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-V-NH ₂
251	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Val]-NH ₂
252	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-NH ₂
253	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-P-NH ₂
254	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Pro]-NH ₂
255	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-I-NH ₂
256	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Arg]-NH ₂

SEQ ID NO:	Sequence*
257	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Phe]-NH ₂
258	Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Phe]-NH ₂
259	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Tyr]-NH ₂
260	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-S-NH ₂
261	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Ser]-NH ₂
262	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-NT-NH ₂
263	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Thr]-NH ₂
265	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-[N-MeAla]-NH ₂
266	Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-Y-NH ₂
274	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Achc]-[Lys(Ac)]-N-[bA]-NH ₂
275	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Spiral Pip]-[Lys(Ac)]-N-[bA]-NH ₂
276	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[DiethylGly]-[Lys(Ac)]-N-[bA]-NH ₂
277	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acbc]-[Lys(Ac)]-N-[bA]-NH ₂
278	Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeOrn]-[Lys(Ac)]-N-[bA]-NH ₂
289	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[2-Nal]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂

SEQ ID NO:	Sequence*
290	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-H-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂
291	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[His_3Bom]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂
292	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[His_Bzl]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂
293	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[His_Bzl]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH ₂
323	Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH ₂ ;
326	Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-NH ₂ ;
327	Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[a-MePhe]-NH ₂ ;
339	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Sarc]-NH ₂ ;
341	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-G-NH ₂ ;
342	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-A-NH ₂ ;
343	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-R-NH ₂ ;
344	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Lys]-NH ₂ ;
345	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Arg]-NH ₂ ;
346	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Phe]-NH ₂ ;

SEQ ID NO:	Sequence*
347	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)Tyr]-NH ₂ ;
348	Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[(D)2-Nal]-NH ₂ ; or
354	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-N-[(D)Asn]-NH ₂ ;
356	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(IVA)]-N-[(D)Leu]-NH ₂ ;
357	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(cyclohexanoic)]-N-[(D)Leu]-NH ₂ ;
358	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(octanoic)]-N-[(D)Leu]-NH ₂ ;
359	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(C(O)CH ₂ Ph)]-N-[(D)Leu]-NH ₂ ;
360	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(trifluoropropionic)]-N-[(D)Leu]-NH ₂ ; or
361	Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(valeric)]-N-[(D)Leu]-NH ₂

or a pharmaceutically acceptable salt or solvate thereof, wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof comprises a disulfide bond between two Pen residues or a thioether bond between Abu and Cys;

and

wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof inhibits the binding of an interleukin-23 (IL-23) to an IL-23 receptor.

85. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:
 Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂; (SEQ ID NO: 323); or
 and wherein the peptide inhibitor is cyclized via a Abu-C thioether bond;
 or a pharmaceutically acceptable salt or solvate thereof.

86. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
 [Lys(Ac)]-N-H-NH₂ (SEQ ID NO: 248);
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
 [Lys(Ac)]-N-[(D)Val]-NH₂ (SEQ ID NO: 251);
 Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
 N-[(D)Arg]-NH₂ (SEQ ID NO: 256);
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
 [Lys(Ac)]-N-[(D)Phe]-NH₂ (SEQ ID NO: 258);
 Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
 N-[(D)Tyr]-NH₂ (SEQ ID NO: 259);
 Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
 N-S-NH₂ (SEQ ID NO: 260);
 Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
 N-[(D)Ser]-NH₂ (SEQ ID NO: 261);
 Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
 N-[(D)Thr]-NH₂ (SEQ ID NO: 263);
 Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
 N-[Aib]-NH₂ (SEQ ID NO: 264);
 Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
 [N-MeAla]-NH₂ (SEQ ID NO: 265);
 Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Achc]-[Lys(Ac)]-N-
 [bA]-NH₂ (SEQ ID NO: 274);
 Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[DiethylGly]-[Lys(Ac)]-
 N-[bA]-NH₂ (SEQ ID NO: 276);

Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[Acbc]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 277); or
 Ac-[Pen]-N-T-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeOrn]-[Lys(Ac)]-N-[bA]-NH₂ (SEQ ID NO: 278);
 and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via a Abu-C thioether bond;
 or a pharmaceutically acceptable salt or solvate thereof.

87. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:
 Ac-[Pen]-NT-[W(7-Me)]-Q-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLeu]-[Lys(Ac)]-[(D)His]-[bA]-NH₂ (SEQ ID NO: 215);
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-R-NH₂ (SEQ ID NO: 243);
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[NMeArg]-NH₂ (SEQ ID NO: 246);
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[bhPhe]-NH₂ (SEQ ID NO: 247);
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-V-NH₂ (SEQ ID NO: 250);
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-P-NH₂ (SEQ ID NO: 253);
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Pro]-NH₂ (SEQ ID NO: 254);
 Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-I-NH₂ (SEQ ID NO: 255);
 Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Phe]-NH₂ (SEQ ID NO: 257);
 or
 Ac-[(D)Arg]-[Abu]-Q-T-[W(7-Me)]-[Lys(Ac)]-[Cys]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Lys]-[Sarc]-NH₂; (SEQ ID NO: 323);
 and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via a Abu-C thioether bond;

or a pharmaceutically acceptable salt or solvate thereof.

88. The peptide inhibitor of claim 83, wherein the peptide inhibitor comprises or is:

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-[2-Nal]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 289); or


Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-H-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂ (SEQ ID NO: 290);

and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or via a Abu-C thioether bond;


or a pharmaceutically acceptable salt or solvate thereof.

89. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:


Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-H-NH₂ (Seq. ID. No. 248)




Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Tyr]-NH₂ (Seq. ID. No. 259)




Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Ser]-NH₂ (Seq. ID. No. 261)




Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Thr]-NH₂ (Seq. ID. No. 263)



Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-NH₂ (Seq. ID. No. 264)




Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[bA]-NH₂ (SEQ ID NO: 340)




or

Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[Aib]-[(D)Lys]-NH₂ (SEQ ID NO: 344)




and wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond;
or a pharmaceutically acceptable salt or solvate thereof.

90. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-NT-[W(7-Me)]-[Lys(Ac)]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-H-NH₂ (Seq. ID. No. 248)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

91. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
N-[(D)Tyr]-NH₂ (Seq. ID. No. 259)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

92. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
N-[(D)Ser]-NH₂ (Seq. ID. No. 261)




wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

93. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
N-[(D)Thr]-NH₂ (Seq. ID. No. 263)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.


94. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:
Ac-[Pen]-NT-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-
N-[Aib]-NH₂ (Seq. ID. No. 264)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.


95. The peptide inhibitor of claim 83, wherein the peptide inhibitor comprises or is:

Ac-[Pen]-N-T-[W(7-Me)]-[Lys(Ac)]-[Pen]-H-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[(D)Leu]-NH₂ (Seq. ID. No. 290)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.


96. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is: Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-[Lys(Ac)]-N-[Aib]-[bA]-NH₂ (SEQ ID NO: 340)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond; or a pharmaceutically acceptable salt or solvate thereof.

97. The peptide inhibitor of claim 81, wherein the peptide inhibitor comprises or is:

Ac-[Pen]-N-T-[W(7-Me)]-[Cit]-[Pen]-Phe[4-(2-aminoethoxy)]-[2-Nal]-[a-MeLys]-
[Lys(Ac)]-N-[Aib]-[(D)Lys]-NH₂ (SEQ ID NO: 344)



wherein the peptide inhibitor is cyclized via a Pen-Pen disulfide bond;
or a pharmaceutically acceptable salt or solvate thereof.

98. A polynucleotide comprising a sequence encoding the peptide inhibitor of any one of claims 1-97.

99. A vector comprising the polynucleotide of claim 98.

100. A pharmaceutical composition comprising the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-97, and a pharmaceutically acceptable carrier, excipient, or diluent.

101. The pharmaceutical composition of claim 100, further comprising an enteric coating.

102. The pharmaceutical composition of claim 101, wherein the enteric coating protects and releases the pharmaceutical composition within a subject's lower gastrointestinal system.

103. A method for treating an Inflammatory Bowel Disease (IBD), ulcerative colitis, Crohn's disease, Celiac disease (*nontropical Sprue*), enteropathy associated with

seronegative arthropathies, microscopic colitis, collagenous colitis, eosinophilic gastroenteritis, colitis associated with radio- or chemo-therapy, colitis associated with disorders of innate immunity as in leukocyte adhesion deficiency-1, chronic granulomatous disease, glycogen storage disease type 1b, Hermansky-Pudlak syndrome, Chediak-Higashi syndrome, and Wiskott-Aldrich Syndrome, pouchitis resulting after proctocolectomy and ileoanal anastomosis, gastrointestinal cancer, pancreatitis, insulin-dependent diabetes mellitus, mastitis, cholecystitis, cholangitis, pericholangitis, chronic bronchitis, chronic sinusitis, asthma, psoriasis, psoriatic arthritis, or graft versus host disease in a subject, comprising providing to the subject an effective amount of the peptide inhibitor or peptide inhibitor or pharmaceutically acceptable salt or solvate thereof of any one of claims 1-98, or the pharmaceutical composition of any one of claims 101-103.

104. The method of claim 103, wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof or the pharmaceutical composition is provided to the subject by an oral, parenteral, intravenous, peritoneal, intradermal, subcutaneous, intramuscular, intrathecal, inhalation, vaporization, nebulization, sublingual, buccal, parenteral, rectal, intraocular, inhalation, topically, vaginal, or topical route of administration.

105. The method of claim 103 for treating an Inflammatory Bowel Disease (IBD), wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof or the pharmaceutical composition is provided to the subject orally.

106. The method of claim 105, wherein the IBD is ulcerative colitis.

107. The method of claim 105, wherein the IBD is Crohn's disease.

108. The method of claim 103 for treating psoriasis, wherein the peptide inhibitor or pharmaceutically acceptable salt or solvate thereof or the pharmaceutical composition is provided to the subject orally, topically, parenterally, intravenously, subcutaneously, peritoneally, or intravenously.